Genmab — Januar 2018
-
-
Medie: Storbanker ser stadig stort lys i Genmab
Tre store banker har fortsat stor fidus til det danske biotekselskab Genmab og mener, at selskabets aktie skal langt højere op end det nuværende niveau. Kan biotekselskabets guldæg Darzalex vise potentiale i solide kræftformer, kan det endda være med til at retfærdiggøre en kurs på mere end 2900 kr., mener en analytiker.
(medwatch.dk)
-
-
Sebia announces FDA clearance for its Hydrashift 2/4 daratumumab assay http://www.ala.com/sebia-announces-fda-clearance-for-its-hydrashift-24-daratumumab-assay/
-
Novartis results presentation https://www.novartis.com/sites/www.novartis.com/files/q4-2017-ir-presentation.pdf Confirms blockbuster expectation p37 (OMB157) , p64, 65 planned filing 2019. Arzerra for iNHL 2020. p100, 103
-
-
A bit surprising, no? Primary Completion Date : January 3, 2018 -Estimated Study Completion Date : December 20, 2024
https://clinicaltrials.gov/ct2/show/NCT01077518?term=NCT01077518&rank=1 -
er der stadig ingen, der kan fremskaffe SH tallet fra i dag??
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind